Patents-Review.com
ClassID:

111025 ⎘

C12N2760/18734 - CPC Classification

Classification description:

ssRNA viruses negative-sense; Details; Paramyxoviridae; Rubulavirus, e.g. mumps virus, parainfluenza 2,4 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Recent Application in this class:
#1
20260069674
2026-03-12

PIV5-BASED COVID-19 VACCINE

 #2
20260022145
2026-01-22

PREFUSION PIV F IMMUNOGENS AND THEIR USE

 #3
20250319176
2025-10-16

PIV5-BASED COVID-19 VACCINE

 #4
20250223572
2025-07-10

PARAMYXOVIRUS VIRUS-LIKE PARTICLES AS PROTEIN DELIVERY VEHICLES

 #5
20250213669
2025-07-03

ATTENUATED BORDETELLA BRONCHISEPTICA STRAINS, ORAL VACCINES CONTAINING THE ATTENUATED STRAINS, AND METHODS OF MAKING & USE THEREOF

 #6
20250161425
2025-05-22

SIGNAL SEQUENCES FOR NUCLEIC ACID VACCINES

 #7
20240316180
2024-09-26

ATTENUATED MUMPS VACCINE AND USES THEREOF

 #8
20240309053
2024-09-19

RECOMBINANT HUMAN/BOVINE PARAINFLUENZA VIRUS 3 (B/HPIV3) EXPRESSING A CHIMERIC RSV/PIV3 F PROTEIN AND USES THEREOF

 #9
20240101609
2024-03-28

PREFUSION PIV F IMMUNOGENS AND THEIR USE

 #10
20230287055
2023-09-14

Recombinant human parainfluenza virus type 1 expressing a chimeric RSV/HPIV1 f protein and uses thereof

 #11
20230105376
2023-04-06

PIV5-BASED CORONAVIRUS VACCINES AND METHODS OF USE THEREOF

 #12
20220389391
2022-12-08

F-GENOTYPE MUMPS VIRUS ATTENUATED STRAIN AND CONSTRUCTION METHOD THEREFOR AND APPLICATION THEREOF

 #13
20220348887
2022-11-03

Mumps virus as a potential oncolytic agent

 #14
20220267740
2022-08-25

Paramyxovirus virus-like particles as protein delivery vehicles

 #15
20220162567
2022-05-26

PARAMYXOVIRUS VIRUS-LIKE PARTICLES AS PROTEIN DELIVERY VEHICLES

 #16
20220024987
2022-01-27

Prefusion PIV F immunogens and their use

 #17
20220023413
2022-01-27

RECOMBINANT MUMPS VIRUS VACCINE EXPRESSING GENOTYPE G FUSION AND HEMAGGLUTININ-NEURAMINIDASE PROTEINS

 #18
20200277338
2020-09-03

Recombinant human/bovine parainfluenza virus 1 (HPIV1) expressing a chimeric RSV/HPIV1 F protein and uses thereof

 #19
20200224175
2020-07-16

Mumps virus as a potential oncolytic agent

 #20
20200048311
2020-02-13

Prefusion PIV F immunogens and their use

 #21
20190338253
2019-11-07

Paramyxovirus virus-like particles as protein delivery vehicles

 #22
20190216918
2019-07-18

Recombinant mumps virus vaccine

 #23
20180360947
2018-12-20

Compositions and methods for stabilization of active agents

 #24
20180312544
2018-11-01

Recombinant human/bovine parainfluenza virus 3 (B/HPIV3) expressing a chimeric RSV/BPIV3 F protein and uses thereof

 #25
20180228899
2018-08-16

Methods and compositions for therapeutic agents

 #26
20180214538
2018-08-02

Generation of antibodies to tumor antigens and generation of tumor specific complement dependent cytotoxicity by administration of oncolytic vaccinia virus

 #27
20180187163
2018-07-05

Mumps virus as a potential oncolytic agent

 #28
20170321224
2017-11-09

Modified Sendai virus vaccine and imaging vector

 #29
20170258889
2017-09-14

COMPOSITIONS AND METHODS FOR STABILIZATION OF ACTIVE AGENTS

 #30
20170175086
2017-06-22

Paramyxovirus virus-like particles as protein delivery vehicles

 #31
20160228540
2016-08-11

Nasal mucosal vaccine composition

 #32
20160193327
2016-07-07

Mucosal vaccine composition

 #33
20150329874
2015-11-19

Vaccine prepared utilizing human parainfluenza virus type 2 vector

 #34
20150273035
2015-10-01

VACCINATION AGAINST JAPANESE ENCEPHALITIS, MEASLES, MUMPS AND RUBELLA

 #35
20150079077
2015-03-19

METHODS AND COMPOSITIONS FOR THERAPEUTIC AGENTS

 #36
20150037355
2015-02-05

Generation of antibodies to tumor antigens and generation of tumor specific complement dependent cytotoxicity by administration of oncolytic vaccinia virus

 #37
20140220073
2014-08-07

Immunization compositions and methods

 #38
20140186397
2014-07-03

Modified Sendai virus vaccine and imaging vector

 #39
20140079733
2014-03-20

Compositions for canine respiratory disease complex

 #40
20140010840
2014-01-09

Recombinant mumps virus vaccine

 #41
20130273100
2013-10-17

Vaccines with live bacterial isolates for systemic administration

 #42
20130023030
2013-01-24

Recovery of recombinant human parainfluenza virus type 2 (HYPIV2) from cDNA and use of recombinant HPIV2 in immunogenic compositions and as vectors to elicit immune responses against PIV and other human pathogens

 #43
20120014972
2012-01-19

INFLUENZA VIRUS COMPOSITIONS AND METHODS FOR UNIVERSAL VACCINES

 #44
20120009212
2012-01-12

CONJUGATES UTILIZING PLATFORM TECHNOLOGY FOR STIMULATING IMMUNE RESPONSE

 #45
20110189226
2011-08-04

Immunization compositions and methods

 #46
20110143422
2011-06-16

Recovery of recombinant human parainfluenza virus type 2 (HYPIV2) from cDNA and use of recombinant HPIV2 in immunogenic compositions and as vectors to elicit immune responses against PIV and other human pathogens

 #47
20100260796
2010-10-14

Stabilizers for freeze-dried vaccines

 #48
20100119550
2010-05-13

RECOMBINANT MULTIVALENT VACCINE

 #49
20090092635
2009-04-09

HETEROLOGOUS PRIME-BOOST IMMUNIZATION REGIMEN

 #50
20090010963
2009-01-08

Raccoon poxvirus expressing rabies glycoproteins

 #51
20080286848
2008-11-20

Recovery of recombinant human parainfluenza virus type 2 (HPIV2) from CDNA and use of recombinant HPIV2 in immunogenic compositions and as vectors to elicit immune responses against PIV and other human pathogens

 #52
20080096264
2008-04-24

Attenuated parainfluenza virus (PIV) vaccines

 #53
20070258997
2007-11-08

Rescue of mumps virus from CDNA

 #54
20070253972
2007-11-01

Rescue of mumps virus from cDNA

 #55
17865257
2026-03-17

Transient expression of biologic materials